Pharma & Life Sciences

Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors

USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.

Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof

USPTO published Jacobio Pharmaceuticals' patent application (US20260098039A1) for solid forms of Compound I, a potential cancer therapeutic compound, and its salts. The patent covers novel solid forms, preparation methods, pharmaceutical compositions, and therapeutic uses. The application was filed August 16, 2023, and published April 9, 2026.

MHRA-NICE Aligned Pathway Accelerates Patient Access to Medicines by 3-6 Months

The MHRA and NICE launched an aligned pathway that synchronizes regulatory approval with health technology assessment, enabling new medicines to reach NHS patients 3-6 months earlier than previous timelines. This integration brings together the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence to deliver simultaneous regulatory and reimbursement decisions.

CAR T-cell therapy CHT105 trial for refractory lupus nephritis

CAR T-cell therapy CHT105 trial for refractory lupus nephritis

Immunotherapy Trial Before Surgery for Kidney Cancer

ClinicalTrials.gov registered NCT07516366, a Phase 2 clinical trial evaluating pembrolizumab immunotherapy administered before nephrectomy surgery for patients with renal cell carcinoma. The single-arm study will assess pathological complete response rate, event-free survival, and safety endpoints at multiple U.S. trial sites.

AI-Supported Hybrid Closed Loop System AIDANET for Type 1 Diabetes

NLM registered a clinical study on ClinicalTrials.gov evaluating an AI-supported hybrid closed loop system (AIDANET) for automated glucose management in adults with Type 1 diabetes. The single-arm study will assess system safety and effectiveness over a 12-week period using CGM metrics and HbA1c measurements.

Chidamide Sintilimab Bevacizumab Second-Line Neuroendocrine Carcinoma

ClinicalTrials.gov registered a new Phase 2 trial (NCT07518602) evaluating the combination of chidamide, sintilimab, and bevacizumab as second-line treatment for patients with advanced neuroendocrine carcinoma. The single-arm study will assess objective response rate and safety profile of the triple-drug regimen. No compliance obligations are created by this informational registration.

Psilocybin Safety Tolerability Healthy Older Adults Study

The National Institutes of Health registered a clinical trial (NCT07516405) evaluating psilocybin safety and tolerability in healthy older adults. The study will assess how this psychedelic compound is tolerated in subjects aged 60-85. Clinical trial sponsors and researchers should ensure proper registration and protocol compliance.

GC-Globulin Patent Claims Diabetes Treatment

USPTO published patent application US20260098068A1 for GC-globulin or variants for treating diabetes, filed September 22, 2023. The application names David Hodson, Katrina Viloria, and Martin Hewison as inventors and covers compositions and methods for diabetes treatment using the vitamin D-binding protein.

P80 Protein Treatment Method Using Pharmaceutical Composition Comprising Neurotoxin Associated Polypeptide

The USPTO published patent application US20260098066A1 assigned to Prime Bio, Inc., covering a method of treating disorders using a pharmaceutical composition comprising a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 acts as a tight junction modulator to enhance intestinal epithelium permeability, facilitating drug delivery and increasing bioavailability of therapeutic agents including drugs, small molecules, proteins, and biomolecules.